Unrelated CD3/CD19-Depleted Peripheral Stem Cell Transplantation for Hurler Syndrome
Authors:
- Wolfgang SchwingerWSWolfgang Schwinger
- Petra SovinzPSPetra Sovinz
- Martin BeneschMBMartin Benesch
- Herwig LacknerHLHerwig Lackner
- Markus SeidelMSMarkus Seidel
- Volker StrengerVSVolker Strenger
- Daniela SperlDSDaniela Sperl
- Andrea RaichtARAndrea Raicht
- Michaela Brunner-KrainzMBMichaela Brunner-Krainz
- Eduard PaschkeEPEduard Paschke
- Barbara PleckoBPBarbara Plecko
- Christian UrbanCUChristian Urban
- 12 August 2014
- journal article
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 31 (8) , 723-730
Abstract
For patients with mucopolysaccharidosis type IH (MPS1-H; Hurler syndrome), early allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice. One boy and one girl aged 20.5 and 22 months, respectively, with MPS1-H received a conditioning regimen consisting of thiotepa, fludarabine, treosulfan, and ATG. Grafts were peripheral blood stem cells from unrelated donors (10/12 and 11/11 matched), that were manipulated by CD3/CD19 depletion and contained 20.3 and 28.2 × 10(6) CD34+ cells/kg body weight, respectively. Both patients achieved stable hematopoietic engraftment and stable donor chimerism. Neither acute or chronic graft-versus-host disease (GVHD) nor other severe transplant-related complications occurred. At a follow-up of 48 and 37 months, both patients are alive and well with normal levels of α-L-iduronidase and have made major neurodevelopmental progress. Treosulfan-based conditioning offers the advantage of reduced toxicity; the use of unrelated CD3/CD19-depleted peripheral stem cell grafts allows transfusion of high CD34+ cell numbers together with a "tailored" number of CD3+ cells as well as engraftment facilitating cells in order to achieve rapid hematopoietic engraftment while reducing the risk of graft rejection and GVHD. This regimen might be an additional option when unrelated donor HSCT is considered for a patient with MPS1-HKeywords
This publication has 22 references indexed in Scilit:
- Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioningBlood, 2013
- Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I RegistryEuropean Journal of Pediatrics, 2012
- Cord blood and bone marrow transplantation in inherited metabolic diseases: scientific basis, current status and future directionsBritish Journal of Haematology, 2010
- Transplant Outcomes in MucopolysaccharidosesSeminars in Hematology, 2010
- Risk Factor Analysis of Outcomes after Unrelated Cord Blood Transplantation in Patients with Hurler SyndromeTransplantation and Cellular Therapy, 2009
- Mucopolysaccharidosis I: Management and Treatment GuidelinesPediatrics, 2009
- Enzyme Replacement Therapy in Patients Who Have Mucopolysaccharidosis I and Are Younger Than 5 Years: Results of a Multinational Study of Recombinant Human α-l-Iduronidase (Laronidase)Pediatrics, 2007
- A large-scale method for T cell depletion: towards graft engineering of mobilized peripheral blood stem cellsBone Marrow Transplantation, 2002
- Isolation of Highly Purified Autologous and Allogeneic Peripheral CD34+ Cells Using the CliniMACS DeviceJournal of Hematotherapy, 1999
- REVERSAL OF CLINICAL FEATURES OF HURLER'S DISEASE AND BIOCHEMICAL IMPROVEMENT AFTER TREATMENT BY BONE-MARROW TRANSPLANTATIONThe Lancet, 1981